Our study also provides a novel insight that targeting ERRα could be a potential androgen-deprivation strategy for the management of CRPC as pharmacological suppression of its activity could help to attenuate the intracellular production of DHT and AR signaling in prostate cancer cells. This evidence concerns the gene ESRRA and Familial prostate cancer.